This is an observational prospective study. Patients diagnosed with advanced epithelial ovarian cancer (stage IC or higher) since 2008 will be asked to participate in this study by signing an informed consent. Tumour samples will be reviewed to confirm the diagnosis and to select the best regions for tissue sampling to perform the following molecular studies: array-based Comparative Genomic Hybridization and Next Generation Sequencing. Detected mutations will be analysed by Sanger sequencing. FISH probes will be designed and tested on the samples.
Study Type
OBSERVATIONAL
Enrollment
230
Hospital Universitario Severo Ochoa
Leganés, Madrid, Spain
Hospital Universitario HM Sanchinarro - Clara Campal Comprehensive Cancer Center
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Complejo Hospitalario de Navarra
Pamplona, Spain
Number of participants with a genetic profile defined by sequencing that could predict Progression Free Survival (PFS)
Clinical data from the enrolled patients will be recorded and related to the results obtained from sequencing the DNA isolated from tumor samples. Whole exome sequencing (WES) will be used for sequencing DNA isolated from paraffin embedded samples and Whole genome association study (GWAS) for the DNA from frozen samples. The bioinformatics analysis of the sequencing results will allow us to identify altered regions and affected genes and the minimal common regions of imbalance. All detected mutations will be confirmed by Sanger sequencing to ensure the reliability of the findings.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.